Insulet Corporation

NASDAQ:PODD

Medical - Devices

Healthcare
$139.98 -2.82%

-$4.17 today

Market cap
$9.71B
Beta
1.13
P/E (TTM)
33.2
EPS (TTM)
$4.33
52W Low $140.63High $354.88

Volume 2.09M

Average 1.32M

PODD Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Insulet CorporationNASDAQ: PODD

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $801.7M rose 23.5% year over year, behind the +29.4% change in trailing-twelve-month revenue. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 19 analysts of $3.31B (+22.1%) for the fiscal year ending Dec 2026, a slowdown from the +30.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$801.7M+5.3% QoQ
Last fiscal yearDec 2025
$2.71B+30.7% YoY
LTMJun 2026
$3.05B+29.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.5%+17.9%-5.6 pp
1 year+30.7%+22.1%-8.7 pp
3-year CAGR+27.5%+15.1%-12.4 pp
5-year CAGR+12.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.71B USD
Year-over-year change
+30.7%
4-year CAGR
+25.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PODD compares with its peers on the latest reported figures

  • PODD's LTM Jun 2026 revenue of $3.05B is the 2nd highest of the 5 companies compared; the peer median is $568.89M.
  • Its year-over-year change of +29.4% is the 3rd highest of 5, against a peer median of +36.7%.
  • Over three fiscal years its annual growth of +27.5% compares with a peer median of +23.1%.
PODD Competitors Peer median
Revenue for PODD and competitors
Company Period LTM YoY 3-year CAGR
DXCMDexCom, Inc.LTM Jun 2026$4.97B +15.5%+17.0%
PODDInsulet CorporationLTM Jun 2026$3.05B +29.4%+27.5%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$1.03B -6.8%+8.2%
BBNXBeta Bionics, Inc.LTM Mar 2026$110.24M +57.9%+724.3%
SENSSenseonics Holdings, Inc.LTM Mar 2026$40.71M +71.9%+29.1%
Peer median (excluding PODD) $568.89M+36.7%+23.1%

Competitors are the stored peer set for PODD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.31B1.7B2.07B2.71B
Cost of Revenue346.7M499.7M537.2M625.9M768.2M
Gross Profit752.1M805.6M1.16B1.45B1.94B
Gross Margin68.4%61.7%68.3%69.8%71.6%
Research & Development160.1M180.2M205M219.6M301.1M
Selling, General & Admin466M587.8M734.9M917.2M1.17B
Operating Expenses626.1M768M939.9M1.14B1.47B
Depreciation & Amortization57.4M63.2M72.8M80.8M90.4M
EBITDA139.6M109M323.6M423.7M509.6M
EBITDA Margin12.7%8.4%19.1%20.5%18.8%
Operating Income126M37.6M220M308.9M473.8M
Operating Margin11.5%2.9%13.0%14.9%17.5%
Interest Income500K9.3M28.6M39.5M34.7M
Interest Expense61.7M36M36.2M42.7M79.7M
Other Income / Expenses(105.5M)(27.8M)(5.4M)(8.7M)(134.3M)
Income Before Tax20.5M9.8M214.6M300.2M339.5M
Pre-Tax Margin1.9%0.8%12.6%14.5%12.5%
Income Tax Expense3.7M5.2M8.3M(118.1M)92.4M
Net Income16.8M4.6M206.3M418.3M247.1M
Net Margin1.5%0.4%12.2%20.2%9.1%
EPS (Basic)0.250.072.965.973.51
EPS (Diluted)0.250.072.945.783.48
Weighted Avg Shares67.7M69.38M69.75M70.08M70.35M
Weighted Avg Shares (Diluted)68.58M69.91M73.63M73.89M71.89M

Insulet Corporation

NASDAQ:PODD

Intrinsic Alpha fair value

Locked

Current Price

$139.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.